RecruitingPhase 4NCT05004987

Aβ Dynamics in LLMD

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Nunzio Pomara, MD
NYU Langone Health
Intervention
Escitalopram Oxalate(drug)
Enrollment
60 target
Eligibility
60 years · All sexes
Timeline
2022 – 2027

Study locations (2)

Collaborators

National Institute on Aging (NIA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05004987 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials